Merck KGaA has concluded the previously announced acquisition of SpringWorks Therapeutics for an enterprise value of €3bn ($3.4bn), after receiving regulatory approvals and fulfilling customary ...

The transaction, finalized following regulatory clearance, includes two FDA-approved rare tumor therapies: Ogsiveo for ...

A little over two months after it was announced, Germany-based life sciences firm Merck KGaA said Tuesday that it has ...

Merck KGaA, Darmstadt, Germany has closed the acquisition of SpringWorks Therapeutics Inc. for an enterprise value of $3.4 billion.

Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced that it has closed the acquisition ...

Detailed price information for Candel Therapeutics Inc (CADL-Q) from The Globe and Mail including charting and trades.

The Fiera Capital SMID Cap Growth SMA returned -10.7% (net of fees), and slightly outperformed its benchmark for Q1 2025.

Patients with rare diseases are increasingly working to find and fund their own cures. But should they have to?

The biotech sector remains one of the most dynamic areas of the market, driven by clinical breakthroughs, regulatory ...

Logo On June 1, the cancer community gathered to mark the 38th National Cancer Survivors Day and bring attention to the c ...

Detailed price information for Wave Life Sci Ord Sh (WVE-Q) from The Globe and Mail including charting and trades.